Collaboration aims to accelerate human genome analysis and enable advancements
in personalized healthcare.
YORKTOWN HEIGHTS, N.Y. & BRANFORD, Conn.–(Business Wire)–
Roche (SWX:RO)(SWX:ROG)(Pink Sheets: RHHBY) and IBM (NYSE: IBM) announced today
an agreement to develop a nanopore-based sequencer that will directly read and
decode human DNA quickly and efficiently. Focused on advancing IBM`s recently
published “DNA Transistor” technology, the collaboration will take advantage of
IBM`s leadership in microelectronics, information technology and computational
biology and Roche`s expertise in medical diagnostics and genome sequencing.
The novel technology, developed by IBM Research, offers true single molecule
sequencing by decoding molecules of DNA as they are threaded through a
nanometer-sized pore in a silicon chip. The approach holds the promise of
significant advantages in cost, throughput, scalability, and speed compared to
sequencing technologies currently available or in development.
“By merging computational biology, biotechnology, and nanotechnology skills, we
are moving closer to producing a system that can quickly and accurately
translate DNA into medically-relevant genetic information,” said Ajay Royyuru,
Senior Manager of the Computational Biology Department at IBM Research. “The
challenge of all nanopore-based sequencing technologies is to slow and control
the motion of the DNA through the nanopore. We are developing the technology to
achieve this so that the reader can accurately decode the DNA sequence.”
Ultimately, the technology has the potential to improve throughput and reduce
costs to achieve the vision of whole human genome sequencing at a cost of $100
to $1,000. Having access to an individual`s personal genetic code could advance
the quality of medical care by identifying persons who will gain the greatest
benefit from a particular medicine and those who are at most risk of adverse
reaction.
“Sequencing is an increasingly critical tool for personalized healthcare. It can
provide the individual genetic information necessary for the effective diagnosis
and targeted treatment of diseases,” explained Manfred Baier, Head of Roche
Applied Science. “We are confident that this powerful technology – plus the
combined strengths of IBM and Roche – will make low-cost whole genome sequencing
and its benefits available to the marketplace faster than previously thought
possible.”
As part of the agreement, Roche will fund continued development of the
technology at IBM and provide additional resources and expertise through
collaboration with Roche`s sequencing subsidiary, 454 Life Sciences. Roche will
develop and market all products based on the technology.
Roche`s investment in future genomic technologies builds upon the strength of
its currently available 454 Sequencing Systems, which generate hundreds of
thousands of long, high quality sequencing reads in hours. The technology is
available for large-scale genomic analysis with the GS FLX System and for
benchtop sequencing with the GS Junior System. Shown to provide significant
medical value in targeted resequencing applications for virology and oncology
research, 454 Sequencing Systems are poised to be first next-generation
sequencing technology to move from the laboratory to the clinic.
For more information on 454 Sequencing Systems, visit www.454.com.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is
the world`s largest biotech company with truly differentiated medicines in
oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in
diabetes management. Roche`s personalised healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the health,
quality of life and survival of patients. In 2009, Roche had over 80`000
employees worldwide and invested almost 10 billion Swiss francs in R&D. The
Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a
wholly owned member of the Roche Group. Roche has a majority stake in Chugai
Pharmaceutical, Japan. For more information: www.roche.com.
About IBM
For more information, visit www.ibm.com/smarterplanet
For life science research only. Not for use in diagnostic procedures.
454, 454 SEQUENCING, 454 LIFE SCIENCES, GS FLX and GS JUNIOR are trademarks of
Roche.
IBM is a registered trademark of International Business Machines Corporation in
the United States, other countries, or both.
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: burkhard.ziebolz@roche.com
or
454 Life Sciences Corporation, a Roche Company
Dr. Ulrich Schwoerer
Phone: +1 203 871 2300
Email: ulrich.schwoerer@roche.com
or
IBM
Michael Loughran
Phone: +1 914 945 1613
Email: mloughra@us.ibm.com
Copyright Business Wire 2010
